1. Home
  2. JTAI vs CDIO Comparison

JTAI vs CDIO Comparison

Compare JTAI & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$0.08

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$2.01

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JTAI
CDIO
Founded
2018
2017
Country
United States
United States
Employees
8
9
Industry
Blank Checks
Biotechnology: Commercial Physical & Biological Resarch
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
CDIO
Price
$0.08
$2.01
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$0.40
N/A
AVG Volume (30 Days)
19.0M
323.6K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$171,906.75
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.18
52 Week High
$4.70
$7.91

Technical Indicators

Market Signals
Indicator
JTAI
CDIO
Relative Strength Index (RSI) 32.07 39.85
Support Level N/A $1.64
Resistance Level $0.13 $4.60
Average True Range (ATR) 0.01 0.32
MACD 0.01 -0.11
Stochastic Oscillator 20.57 27.84

Price Performance

Historical Comparison
JTAI
CDIO

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Share on Social Networks: